biosimilars

What Are Biosimilars and Why They Matter for Your Prescription Costs

July 28, 2026

Key Takeaways

Biosimilars saved $20 billion in 2024 and typically cost 50% less than reference biologics at launch.
FDA approval ensures biosimilars are safe and effective through rigorous testing.
Biosimilars differ from generics in complexity and manufacturing.
Switching between reference products and biosimilars is safe.
Market competition drives down costs as each additional biosimilar competitor reduces average market prices by 10-13%.

A molecular structure with an abstract blue color background

The Inside Rx Blog

Get the Inside Scoop on tips & tricks that may help your family save on prescriptions!

Subscribe to stay up to date with the latest news and tips

Biosimilars saved over $20 billion in 2024, yet a large share of patients have no awareness of these lower-cost alternatives to biologic medications. Biologics account for 70% or more of total prescription drug spending, but biosimilar adoption continues to trail due to limited awareness among both providers and patients. Biosimilars are highly similar biologic drugs that match their reference product's safety and efficacy profile while costing a fraction of the price. This article covers what biosimilars are, how they differ from generics, how FDA approval works, and where the real-world savings actually show up.

What Are Biosimilars

Understanding Biologic Medications

Biologic medications differ from conventional drugs at a fundamental level, both in composition and production. Biologics originate from living organisms, including animal and plant cells, bacteria, and yeast. These medications can consist of sugars, proteins, living cells, tissues, or combinations of these natural elements, making them far more structurally complex than chemically synthesized drugs.

The manufacturing process reflects that complexity. Production typically takes months, with every step requiring precise control and monitoring. Minor changes during manufacturing can alter the final product, which is why the process itself is considered to define the product. Conventional chemical drugs, manufactured through relatively standardized synthesis protocols, do not carry this same sensitivity to process variation.

How Biosimilars Are Developed

Biosimilar development follows three defined stages: characterization and process perfection, confirmation of biosimilarity, and regulatory approval. The first stage involves a thorough examination of the reference biologic's structure and function. Manufacturers use advanced biological technologies and highly sensitive analytical tools to engineer a biosimilar molecule that matches the reference product's quality attributes.

The development path requires reverse engineering, as manufacturers typically do not have access to the original cell line used for the reference biologic. Multiple batches of the reference product are analyzed, analytical and functional characterizations are performed, and manufacturing processes are built around the quality attributes established through that analysis. Similarity testing occurs at multiple points throughout development, with each stage of the manufacturing procedure optimized iteratively until the process reliably produces a highly similar molecular structure.

Key Characteristics of Biosimilars

The FDA requires that a biosimilar be highly similar to its FDA-approved reference product with no clinically meaningful differences. Specifically, biosimilars must be derived from the same types of source materials, administered at the same strength and dosage, delivered through the same route, and provide the same treatment benefits. The FDA's standard centers on no clinically meaningful differences in safety, purity, and potency.

Minor variation in clinically inactive components is permitted, but all critical quality attributes that determine molecular function must remain highly similar. The risk and benefit profile of a biosimilar, including potential side effects, is the same as that of the reference biologic. Both products complete rigorous FDA review prior to approval, with ongoing safety monitoring and quality controls maintained throughout production.

Biosimilars vs Generics: Understanding the Difference

Manufacturing Process Comparison

Biosimilars and generics are frequently grouped together, but the two products differ in fundamental ways. Generics are exact chemical copies of brand-name drugs, containing identical active ingredients. Biosimilars are highly similar, but not chemically identical, to their reference biologics.

The difference comes down to how each is made. Generic medications are produced through precise chemical synthesis in controlled laboratory settings, yielding small molecules with well-defined, reproducible structures. Every manufactured lot produces the same active ingredient. Biosimilars originate from living systems, yeast, bacteria, or mammalian cells, that are genetically engineered to produce specific molecules. The large, complex protein structures involved in biologic production mean that natural variation occurs within and between manufacturing lots.

Biosimilar manufacturers must reverse-engineer the reference product's production process without access to the original cell line, developing proprietary cell cultures and methods that introduce slight variations from the reference product. Generic manufacturers, by contrast, replicate known chemical formulas.

Approval Requirements

Generic medications follow the Abbreviated New Drug Application pathway. Manufacturers demonstrate pharmaceutical equivalence and bioequivalence through studies with 24-36 healthy volunteers, and the full process typically takes 3-4 years.

Biosimilars face considerably more scrutiny through the Biologics License Application under section 351(k). Manufacturers must establish the same amino acid sequence, similar higher-order structures, biological activities, and product variants as the reference product. Clinical trials require actual patients, not just healthy volunteers, and development spans 7-8 years at a cost of $100-200 million. Generic development, for comparison, runs $1-4 million.

Cost Savings Potential

Generic medications saved the healthcare system over $440 billion in 2023 alone, with patients typically paying 80-85% less than branded versions.

Biosimilar savings are substantial, though on a different scale. Since 2015, biosimilar use has generated $56 billion in healthcare savings, including $20 billion in 2024. Biosimilar prices average 50% less than reference biologics at launch, and biosimilar market entry has also pulled down reference biologic prices by an average of 25% , a secondary savings effect that extends beyond biosimilar users alone.

How FDA Approval Ensures Biosimilar Safety and Effectiveness

Clinical Testing Requirements

FDA approval for biosimilars rests on comparative data across three categories: analytical studies providing structural and functional similarity data, animal studies offering toxicology or pharmacology information, and clinical studies confirming the biosimilar moves through the body identically to the reference product. Each data type serves a distinct role in building the totality of evidence required for approval.

The FDA issued updated guidance in October 2025 that streamlines biosimilarity study requirements. The agency determined that appropriately designed pharmacokinetic studies and immunogenicity assessments may be sufficient when analytical assessments already support biosimilarity. Clinical efficacy studies, which add 1-3 years and cost $24 million on average, frequently contribute little additional information to the biosimilarity assessment. The updated guidance reflects the FDA's position that comparative analytical assessments are more sensitive indicators of biosimilarity than clinical efficacy studies.

Interchangeability Status

Not all FDA-approved biosimilars carry interchangeable status. This designation allows a biosimilar to be substituted for the reference product at the pharmacy level without prescriber intervention, subject to individual state pharmacy laws. Manufacturers must apply separately for this designation and demonstrate that the product produces the same clinical result as the reference product in any given patient.

Switching studies, where patients alternate between the reference product and the biosimilar, are the standard method used to support interchangeability applications. One distinction worth noting: interchangeable status does not indicate a higher level of safety or effectiveness compared to non-interchangeable biosimilars. Both categories meet the same FDA standards for quality and similarity.

Switching Between Reference Products and Biosimilars

A systematic FDA review of switching data across 5,252 patients and 44 switch treatment periods found zero difference in death risk, serious adverse events, and treatment discontinuations between patients who switched and those who remained on the reference product. Immunogenicity outcomes, including incidences of antidrug antibodies and neutralizing antibodies, were also comparable between switched and non-switched patients. The findings held regardless of reference product class, the direction of the switch, or the number of times patients switched.

How Biosimilars Lower Your Prescription Costs

Direct Cost Savings for Patients

Most biosimilars price at 25% or more below their reference products. At launch, the average biosimilar costs 50% less than its reference biologic. Between 2015 and 2023, biosimilar use generated $23.60 billion in healthcare system savings.

Patient out-of-pocket costs tell a more nuanced story. Among claims with nonzero costs, biosimilars averaged $707 per claim versus $911 for reference biologics. That said, biosimilar competition has not systematically reduced patient spending across all cases , a gap that points to the need for targeted policy action.

Impact on Insurance Premiums and Coverage

Insurers see immediate benefit through reduced payment rates when biologic prices fall. Commercial insurers may pass a portion of those savings to enrollees through lower premiums over time. For Medicare, lower biologic spending translates directly to reduced costs for taxpayers.

Market Competition Effects

The number of competitors in a given market is a key driver of price reduction. Each additional biosimilar entrant reduces the average market price by 10% to 13%. Research confirms that biosimilar competition and increased market concentration produce statistically significant price declines specifically in high-cost biologic markets.

Real-World Savings Examples

The oncology segment offers a clear illustration. Biosimilar cancer medicines cut spending growth roughly in half since 2019, contributing to $18 billion in savings on cancer treatments in 2020 alone. Looking ahead, projections estimate biosimilars will reduce direct biologic spending by $54 billion between 2017 and 2026.

The Inside Rx prescription discount card works like a coupon to save on the cost of prescription medication at your local pharmacy.

Lexapro

^$ 518.38

Tablet, 5 Mg

30 Tablets

Wegovy

^$ 149.00

Tablet, 1.5 Mg

30 Tablets

Conclusion

Biosimilar adoption continues to trail despite a well-established FDA approval framework and documented cost savings across the healthcare system. The core issue remains awareness, providers and patients who understand how biosimilars are evaluated, how they compare to reference products, and where savings are most likely to appear are better positioned to make formulary and prescribing decisions that reflect both clinical and cost priorities. Inside Rx supports that process by connecting patients with lower-cost medication options for those who need affordable access to prescription medications.

References

Topics:

Prescription Savings Health Tips for Women Health Tips for Men